Rene Bernards - Jan 20, 2025 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
Director
Signature
/s/ Rene Bernards
Stock symbol
LIXT
Transactions as of
Jan 20, 2025
Transactions value $
$0
Form type
4
Date filed
1/22/2025, 01:13 PM
Previous filing
Oct 29, 2024
Next filing
Apr 2, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +4.17K $0.00 4.17K Jan 20, 2025 Common 4.17K $2.33 Direct F1
holding LIXT Options to Purchase Common Stock 5.3K Jan 20, 2025 Common 5.3K $1.30 Direct
holding LIXT Options to Purchase Common Stock 10K Jan 20, 2025 Common 10K $2.37 Direct
holding LIXT Options to Purchase Common Stock 4.15K Jan 20, 2025 Common 4.15K $2.37 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective January 20, 2025, the reporting person was granted stock options to purchase an aggregate of 4,166 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.